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Horses infected with equine infectious anemia virus (EIAV) have recurrent episodes of viremia which are eventually
controlled, but the immune mechanisms have not been identified. Antibodies were detected to the surface of EIAV-infected
cells within 1 month postinfection and remained for at least 3.5 years postinfection. These antibodies recognized cell
surface-exposed envelope (Env) glycoproteins, but could not mediate antibody dependent cellular cytotoxicity (ADCC) using
EIAV-WSU5-infected equine kidney (EK) cells as targets and peripheral blood mononuclear cells (PBMC) or polymorphonu-
clear cells (PMN) as effector cells. Furthermore, purified IgG antibodies from horses infected with either EIAV-WSU5 or
EIAV-Wyo did not mediate ADCC of infected target cells. Armed effector cells could not be detected in infected horse blood
nor could effector cells be prearmed by incubation with serum antibodies to cell surface antigens. The use of EIAV-WSU5-
infected equine macrophages as target cells did not result in ADCC. In contrast, serum antibody from EHV-1 vaccinated
horses and PBMC or PMN as effector cells caused ADCC of EHV-1-infected EK cells. These results indicate that ADCC is
not involved in the control of EIAV in carrier horses. q 1997 Academic Press
increase in the number of days postinfection when se-INTRODUCTION
roconversion occurred (Rushlow et al., 1990).
EIAV is a lentivirus of horses that causes recurrent The presence of unique cell surface antigens following
episodes of cell-free plasma viremia with concurrent infection of equine dermal (ED) cells with EIAV (McGuire
fever, thrombocytopenia, and anemia. Clinical episodes and Crawford, 1978) and serum antibodies to the EIAV
occur over the first year of infection with each episode Env glycoproteins (O’Rourke et al., 1988; Perryman et al.,
being associated with an antigenically distinct virus 1990) indicated that antibody dependent cellular cytotox-
isolate as defined by virus neutralizing antibody assays icity (ADCC) may play a role in EIAV control. However,
(Kono et al., 1973) and the control of the initial viremic two papers have been published on ADCC in horses
episode is mediated by lymphocyte responses as indi- infected with EIAV with conflicting results. A lack of
cated by the inability of combined immunodeficient Ara- ADCC activity was originally reported (Fujimiya et al.,
bian foals to terminate viremia (Perryman et al., 1988). 1979) followed by a second report that detected ADCC
Most horses control EIAV and develop a carrier state activity only during the first viremic episode following
that also appears to be associated with immunological infection (Gerencer et al., 1989). Studies from other lenti-
control as indicated by the recrudescence of viremia viral infections have determined that ADCC mediating
and disease in carrier horses treated with cyclophos- antibodies are present in HIV-infected humans (Kenealy
phamide (Kono et al., 1976) or dexamethasone (Kono et al., 1987; Koup et al., 1989; Tanneau et al., 1990; Nixon
et al., 1976; Tumas et al., 1994b). Following infection of et al., 1992), HIV-infected chimpanzees (Belo et al., 1991),
horses with EIAV, neutralizing antibodies (Kono, 1968; SIV-infected macaques (Ohkawa et al., 1995), and sheep
O’Rourke et al., 1989), complement-fixing antibodies infected with maedi-visna (Tuboly et al., 1991). ADCC
(Kono et al., 1966), complement-inhibiting antibodies mediating antibodies predominantly recognize the viral
(McGuire et al., 1971), and cytotoxic T lymphocytes Env glycoproteins, surface unit (SU), and transmembrane
(McGuire et al., 1994a) have been identified. The im- (TM) (Kenealy et al., 1987; Koup et al., 1989; Tanneau
mune mechanism responsible for the control of viremia et al., 1990) in HIV-infected humans, and the epitopes
has not been identified, but passive transfer of heat- recognized are in the conserved regions of the SU and
inactivated plasma from carrier horses given prior to TM (Nixon et al., 1992).
infection resulted in decreased clinical illness and an The identification of immune mechanisms which can
function in the face of continually changing viral protein
epitopes will increase the understanding of lentivirus/
1 Current address: Department of Animal Sciences, Washington State host interactions and may lead to the identification ofUniversity, Pullman, WA 99164-6310.
immune responses capable of prolonging the asymptom-2 To whom correspondence and reprint requests should be ad-
dressed. atic stage. The purpose of this research was to identify
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the viral proteins expressed on the surface of EIAV-in- ml of growth medium, and incubated in a shaking incuba-
tor (377, 200 rpm) for 2 hr. This maximized the reexpres-fected equine kidney (EK) cells and to analyze different
IgG isotype antibodies binding to these cell surface-ex- sion of cell surface antigens following trypsinization,
while minimizing cell death. Cells were labeled for flowposed viral proteins for their ability to mediate ADCC
activity. cytometry (Tumas et al., 1994a) with serum, and bound
antibody was detected with goat anti-equine immuno-
globulin antibodies conjugated to 5-([4,6-dichlorotriazin-MATERIALS AND METHODS
2-yl]amino)fluorescein (FITC) (Chemicon International,
Horses Inc., Temecula, CA). All data using EK cells were ac-
quired using unfixed cells in the presence of 1 mg/mlEffector cells were isolated from blood from Arabian
propidium iodide (Sigma Chemical Co.). Macrophagesmares between the ages of 18 and 24 years maintained
were scraped from 25-cm2 tissue culture flasks and incu-at Washington State University. Horses infected with
bated with FITC-conjugated serum immunoglobulin fromEIAV-WSU5 were mixed breed ponies (McGuire et al.,
either a normal horse or an EIAV-Wyo infected horse.1994a). Horses infected with EIAV-Wyo were infected by
Live macrophages were identified by fluorescence fol-iv injection of whole blood from EIAV-Wyo-infected
lowing exposure to dihydroethidium (Molecular Probes,horses. All horses were maintained according to institu-
Inc., Eugene, OR). Therefore in all flow cytometry experi-tional animal care and use committee guidelines.
ments, only live cells were analyzed on a FACSort or
FACScan equipped with a Power Macintosh 7100/80Cell cultures
computer and CellQuest software (Becton-Dickinson,
All EK cells used in these experiments were from a San Jose, CA).
kidney biopsy of an adult mixed breed pony or a kidney
from a normal Arabian foal taken at necropsy. EK cells Target cells for ADCC assays
were maintained as described previously (O’Rourke et al.,
EK cells were labeled overnight with 51Cr in tissue1988) in minimal essential medium (MEM) supplemented
culture flasks and used as targets. Labeling medium waswith 10 mM HEPES, 1.75 g/L sodium bicarbonate, and
growth medium containing 50 mCi/ml 51Cr. Normal and5% calf serum.
EHV-1-infected EK cells at the same passage as theEK cells were infected with 1 m.o.i. of EIAV-WSU5 in a
EIAV-infected EK cells were used as negative and posi-small amount of medium and incubated at 377 overnight.
tive controls, respectively. Target EK cells were washedVirus was removed the next day and fresh medium
once in the flask with MEM without serum, lifted withadded. Cells were not used for any experiments until
ATV, and washed three times with MEM plus 5% BCS in⁄6 days postinfection because live-cell flow cytometry
50-ml conical centrifuge tubes. Labeled EK cells wereexperiments indicated this was the first day of maximal
resuspended in assay medium (RPMI 1640 containingsurface antigen expression of EIAV proteins. EK cells
20 mM HEPES, 1.75 g/L sodium bicarbonate, and 10%were infected with 0.17 m.o.i. of EHV-1. Viruses were
FCS) at 2.66 1 105 cells/ml and 75 ml was added to eachadded to 150-cm2 flasks in 10 ml of medium and cells
assay well.were used 20 hr later.
Macrophage cultures were started from heparinized
ADCC assaysblood collected from normal, uninfected adult horses.
Peripheral blood mononuclear cells (PBMCs) were ob- PBMC and polymorphonuclear cells (PMN) isolated
tained using Histopaque 1077 (Sigma Chemical Co., St. from normal, uninfected adult horses were used as ef-
Louis, MO) as described (Wyatt et al., 1988) and macro- fector cells in all ADCC assays. PBMC and PMN were
phages were isolated (Freundlich and Avdalovic, 1983; isolated from whole blood and red blood cells were lysed
Maury, 1994). Macrophages were maintained as de- using 0.87% Tris–ammonium chloride, pH 7.2 (Wyatt et
scribed (Maury, 1994) and infected with 1 m.o.i. of EIAV- al., 1988). Effector cells were resuspended in assay me-
WSU5, as done with EK cells. The macrophage cultures dium and the viability was determined using trypan blue
were characterized by morphology and the ability of dye exclusion. Replicates of six with effector to target93% of the cells to phagocytize latex beads (Tumas cell ratios of 50:1 or 100:1 were incubated for 8 or 17 hr,
et al., 1994a). Live-cell flow cytometry determined that and 50% of the supernatant was used to determine 51Cr
maximal surface antigen expression occurred at 4 days release in a b-plate reader (Wallac, Gaithersburg, MD).
postinfection and subsequent experiments using macro- The formula used to determine SE of the percentage of
phages were done at this time. specific lysis took into account the variability occurring
in both the test and the control wells (Siliciano et al.,Fluorescent flow cytometry
1985). ADCC assays using macrophages as target cells
were done in a similar manner except that experimentalNormal EK cells, EIAV-infected EK cells, and EHV-1-
infected EK cells were lifted from 150-cm2 flasks with 4 and control wells were done in replicates of three. Spon-
taneous release defined as the mean of wells containingml ATV, placed in 50-ml conical centrifuge tubes with 15
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EK cells (Fig. 2). Titers were maximal within 1 month postin-
fection and remained at near maximal levels over the 2-
year observation period. Serum samples from a third horse,
H507, had titers ranging from 2100 to 2500 between 1.5
and 3.5 years postinfection. Following detection of serum
antibodies binding cell surface EIAV Env glycoproteins, se-
rum samples were tested for ADCC activity.
ADCC activity of EIAV serum antibodies
An ADCC assay was developed and several variables
were tested including serum dilution, incubation time,
target to effector cell ratios, and the effect of preincuba-
tion of serum antibodies with effector or target cells. At
a serum dilution of 1:30, no ADCC activity was detectedFIG. 1. Live-cell flow cytometry of normal and EIAV-infected EK cells
in any of the seven post-EIAV-WSU5 infection serumincubated with pre- and post-EIAV-WSU5 infection horse serum sam-
ples. The overlaid histogram shows surface staining of infected EK samples from H507, H521, or H525. Purified PBMC and
cells incubated in the presence of serum collected prior to infection PMN were used as effector cells because the neutrophil
(- - -), uninfected EK cells incubated with serum collected 4 months is the primary effector cell for ADCC in the horse (Fuji-
postinfection (—), and infected EK cells incubated with serum col-
miya et al., 1979; Stokes and Wardley, 1988) while periph-lected 4 months postinfection ( ). Infected cells were used at 6 days
eral blood monocytes and an unidentified population ofpostinfection and dead cells were gated out using propidium iodide
as the indicator. lymphocytes can also mediate ADCC (Stokes and Ward-
ley, 1988). Altering the incubation period of the assay,
the effector to target cell ratio, and the serum dilution
target and effector cells in the absence of serum or did not result in the detection of ADCC activity. Preincu-
equine IgG was reduced by using macrophage culture bation of serum with target or effector cells did not result
medium (DMEM supplemented with 1.75 g/L sodium bi- in specific lysis of targets nor were prearmed effector
carbonate, 20 mM HEPES, 15% horse serum, and 15% cells detected. To verify that the effector cells could medi-
fetal calf serum). ate ADCC of EK cell targets, a control assay was devel-
oped using an equine herpes virus, EHV-1 (Stokes and
Wardley, 1988).RESULTS
EHV-1 control ADCC assayAntibody responses to EIAV Env glycoproteins on the
surface of EK cells Live-cell flow cytometry was used to demonstrate the
presence of unique cell surface antigens following infec-Live-cell flow cytometry was used to determine if infected
tion of EK cells by EHV-1 and serum antibodies to theseEK cells expressed EIAV-WSU5 antigens on their surface
as reported for ED cells infected with the prototype strain
of EIAV (McGuire and Crawford, 1978). EIAV-infected EK
cells had surface antigen expression as demonstrated by
a significant increase in mean peak channel fluorescence
over uninfected EK cells (Fig. 1) when reacted with serum
collected 1 year post-EIAV-WSU5 infection, but not when
reacted with preinfection serum. Uninfected EK cells did
not react with either serum. Live-cell flow cytometry using
EK cells infected with recombinant vaccinia virus express-
ing the EIAV Env proteins (McGuire et al., 1994a), with EIAV
Gag proteins plus the protease, or with no EIAV proteins
(McGuire et al., 1994b) determined that only EIAV Env pro-
teins were expressed on the surface of EK cells. The serum
used had antibodies to the EIAV Gag proteins detected by
agar gel immunodiffusion.
FIG. 2. Titration of horse serum antibodies to EIAV-WSU5 cell surfaceSequential serum samples from EIAV-WSU5-infected
antigens using live-cell flow cytometry. Normal and infected EK cellshorses were titered using live-cell flow cytometry to deter-
were incubated in the presence of serial dilutions of serum from EIAV-mine if antibodies to surface epitopes of the Env glycopro-
WSU5-infected horses at 0, 1, 4, 8, 12, 16, 20, and 24 months postinfec-
teins were present from 1 to 24 months after infection. The tion. Serum dilutions resulting in binding to cell surface antigens on
antibody titer was the reciprocal of the serum dilution neces- 50% of the infected cells were calculated and the inverse of this serum
dilution was the titer.sary for 50% reduction in signals using EIAV-WSU5 infected
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equine IgG(T) polyclonal serum (Bethyl Laboratories, Inc.,
Montgomery, TX). A standard curve made with purified
IgG spiked with serial dilutions of IgG(T) was used to
quantitate the amount of IgG(T) in fractions from the
DEAE column. All IgG fractions had less than 0.05% con-
taminating IgG(T) and still reacted with the Env proteins
expressed on the surface of EIAV-WSU5-infected EK cells
by live cell flow cytometry.
Purified IgG fractions from EIAV-WSU5-infected horses
were tested for ADCC activity and no killing was detected
using dilutions of 1:30, 1:300, and 1:3000 of 20 mg/ml
IgG. Serum and purified IgG antibodies from three horses
infected with the EIAV-Wyo strain were examined to de-
termine if a more virulent virus isolate would induce IgG
antibodies mediating ADCC activity. Despite reactivity
to EIAV Env glycoproteins expressed on the surface of
infected cells, no killing was detected in these assays
using whole serum or purified IgG.
ADCC assays using EIAV-infected equine peripheral
blood-derived macrophages
To ensure that the lack of ADCC activity in previous
FIG. 3. ADCC of normal and EHV-1-infected EK cells by serum sam- assays was not due to use of the wrong target cell, blood-
ples from horses vaccinated with an EHV-1 vaccine. Assays were done derived macrophage cultures were used as target cells.
using as effector cells either PBMC (A) or PMN (B) from a normal adult
While EK cells support the growth and propagation ofhorse. The effector to target cell ratio was 100:1, incubation time of
EIAV-WSU5, the primary cell infected in vivo is the tissuethe assay was 8 hr, and spontaneous release was below 20% of total
release. macrophage (Sellon et al., 1992). Peripheral blood mono-
nuclear cells were purified and infected with EIAV. Mac-
rophages had detectable EIAV cell surface antigen ex-
antigens following EHV-1 vaccination of horses. Serum pression by live-cell flow cytometry using polyclonal
from six normal horses and three EIAV-infected horses, horse serum antibodies directly conjugated to FITC (Fig.
all vaccinated against EHV-1, had antibodies to the sur- 4). A twofold increase in peak channel fluorescence was
face of EHV-1-infected cells. These sera were tested at apparent when EIAV-infected macrophages were incu-
a 1:30 dilution against EHV-1-infected EK cells (Stokes bated in the presence of post-EIAV infection serum. Even
and Wardley, 1988) and all mediated EHV-1-specific
ADCC activity (Fig. 3), although the specific lysis varied
among horses. The absence of ADCC against EIAV-in-
fected EK cells combined with the ability of the same
serum samples and effector cells to mediate the lysis of
EHV-1-infected EK cells indicated that neither the assay
format nor the effector cells were responsible for the lack
of killing.
ADCC using highly purified equine IgG
Horse IgG(T) antibodies, a subtype of equine IgG, in-
hibit complement activation (McGuire et al., 1971) and
ADCC activity at even low concentrations (Fujimiya et
al., 1979). The presence of Env protein-specific IgG(T)
antibodies in the serum samples of EIAV-infected horses
(O’Rourke et al., 1988) could inhibit ADCC activity. IgG FIG. 4. Live-cell flow cytometry to demonstrate the presence of EIAV
antigens on the surface of macrophages derived from the peripheral blood.was purified from serum samples from two EIAV-infected
EIAV antigens were detected using IgG from a horse infected with EIAV-horses (McGuire et al., 1979) and an ELISA was used to
Wyo conjugated to FITC. As a control, IgG from an uninfected horsedetermine the purity of the IgG fractions. Monoclonal
was conjugated to FITC using the same protocol. Normal macrophages
antibody 2/18.2.1 was used as a positive control because incubated with FITC-conjugated IgG from an EIAV-Wyo-infected horse
it bound only to equine IgG at all concentrations tested. (---); EIAV-WSU5-infected macrophages incubated with FITC conjugated
IgG from an uninfected (—) or EIAV-Wyo infected horse ( ).Contaminating IgG(T) was detected using goat anti-
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though the fluorescence was less than that on infected ADCC activity against EHV-1-infected EK cells (Stokes
and Wardley, 1988) made these cells a likely target forEK cells (Fig. 1), the increase on infected macrophages
was reproducible and statistically significant (P  0.001) lysis by ADCC.
Serum samples were collected from three EIAV in-by the Kolomogorov–Smirnov test (Young, 1977) when
compared to the same serum immunoglobulins incu- fected horses at various times postinfection. Flow cytom-
etry results demonstrated that horses produced antibodybated with uninfected macrophages or FITC-conjugated
normal horse serum immunoglobulins incubated with un- to EIAV-infected cell surface epitopes that were detect-
able for at least the first 3.5 years of infection. ADCCinfected or EIAV-infected macrophages.
Infected macrophage targets were labeled with 51Cr assays using sequential serum samples from these
horses resulted in no specific lysis of EIAV-infected EKovernight and incubated with serum and freshly isolated
PMN were added. Pre-EIAV infection serum and serum target cells using either PBMC or PMN as effector cells
regardless of effector to target cell ratios, length of incu-from three horses infected with EIAV-WSU5 for 1 year
were tested for ADCC activity. When no ADCC activity bation time, and serum dilution. Furthermore, the use of
highly purified IgG from horses infected with EIAV-WSU5was detected using whole serum, purified IgG from one
horse was tested for ADCC activity and again, no specific or EIAV-Wyo strains resulted in IgG antibody binding to
target cells, but no specific lysis using either PBMC orkilling was detected.
PMN as effector cells. A control ADCC assay was devel-
oped using the same EK target cells, the same effectorDISCUSSION
cells, and serum samples from the same EIAV-infected
horses vaccinated against EHV-1. Specific killing of EHV-ADCC has been described following several lentiviral
infections with no clear understanding of its role in con- 1-infected target EK cells occurred with no significant
killing of uninfected target cells by incubation with bothtrolling viral burden or immunopathogenic processes.
This work was done to define ADCC mediating antibod- PBMC and PMN. These results confirmed that the target
cells were not resistant to ADCC and that the effectories following EIAV infection so that their role could be
determined by passive antibody transfer experiments. cells were functional.
The use of peripheral blood-derived macrophages asPrevious work characterizing ADCC activity in horses
determined that ADCC mediating antibodies could be target cells in these ADCC assays resulted in target cells
more closely mimicking the in vivo situation where theinduced following immunization of horses with sheep red
blood cells (Fujimiya et al., 1979) or EHV-1 (Stokes and macrophage is the infected cell (Sellon et al., 1992). Initial
studies indicated that EIAV-infected macrophages ex-Wardley, 1988). Further, it was demonstrated that affinity-
purified equine IgG antibodies mediate ADCC whereas pressed viral antigens on their surface at 2 days postin-
fection and EIAV antigen density on the surface of in-this activity can be blocked by the presence 13% affin-
ity-purified equine IgG(T) (Fujimiya et al., 1979). However, fected cells increased, reaching maximal levels at 4 days
postinfection. Incubation of EIAV-infected equine macro-ADCC activity against EIAV-infected ED cells could not
be demonstrated. Later, ADCC mediating antibodies phages with IgG antibodies in the presence of PBMC or
PMN did not result in detectable ADCC activity.were demonstrated in EIAV-infected horses during the
initial viremic episode with specific lysis increasing until While we have demonstrated EIAV antigens on the
surface of infected EK cells and peripheral blood-derived8 days postinfection (Gerencer et al., 1989). This work
used peripheral blood lymphocytes isolated from the macrophages, have reacted these cells with IgG anti-
body to the exposed EIAV antigens, and have used ef-same horses stimulated with phytohemaglutinin without
the addition of virus as the target cell population. Be- fector cells (either PBMC or PMN) shown to work in
another ADCC system, no ADCC activity was detected.cause the primary infected cell in vivo is the tissue mac-
rophage (Sellon et al., 1992) and peripheral blood mono- The horses were followed over the course of the infec-
tion, from acute disease to the carrier state, without de-cytes express only low levels of viral proteins (Maury,
1994), it is unclear what this assay measured. tecting ADCC mediating antibodies. Although we do not
know why IgG antibodies cannot mediate ADCC, it mayIt was our assumption that ADCC antibodies could be
demonstrated in EIAV-infected horse serum by using a be due to the number and the spacing of EIAV Env protein
molecules on the target cell or to the antibody isotypemore susceptible target cell. EK cells (Montelaro et al.,
1982) are used for virus production and cytotoxicity within the IgG fraction. Whatever the explanation, these
results indicate that ADCC does not play a role in theassays because of the increased number of susceptible/
permissive cells. In this paper, 72% of the EK cells were control of lentiviral replication seen in EIAV following
viremic episodes or during the carrier state.infected with EIAV-WSU5 using live-cell flow cytometry
compared with ED cultures where 30% of the cells are
infected using fluorescent antibody on fixed cells
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